Блог
Последни новини, научни статии и полезна информация за молекулярната онкологична диагностика и персонализираната терапия.
Optimizing oral contraceptive timing: Daytime intake reduces doses and enhances efficacy
Author summary Oral contraceptives (OCs) are widely used to prevent pregnancy and manage reproductive health conditions like endometriosis and polycystic ovary syndrome. However, current OCs often use higher hormone doses than necessary, increasing the risk o…
Rybrevant (Johnson & Johnson) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
Key opportunities include increasing demand for personalized cancer therapies, growth in genomic testing, innovation in targeted treatments for NSCLC, and expansion of combination regimens. Strong potential lies in enhancing antibody-based solutions and estab…
EGFR vs. ALK: How molecular profiling defines lung cancer treatment
In today’s clinical oncology practice, the saying “no two cancers are alike” is more relevant than ever. I recently treated two patients with very similar advanced non-small cell lung cancer (NSCLC) who were both critically ill. However, molecular profiling r…
Merck gets FDA Breakthrough Therapy designation for sac-TMT (NYSE:MRK)
Merck's (MRK) antibody drug conjugate sac-TMT has received FDA Breakthrough Therapy designation for the treatment of EGFR-mutated lung cancer. Read more here.
Johnson & Johnson posts Phase 3 win for lung cancer therapy
J&J said its bispecific antibody Rybrevant in a combination therapy outperformed AstraZeneca's (AZN)Tagrisso as a first-line option in lung cancer. Read more he...
First ever inhalable gene therapy for cancer gets fast-tracked by FDA
A gene therapy that patients breathe in has been found to shrink lung tumours by inserting immune-boosting genes into surrounding cells
Страница 5 от 13 • Общо 75 статии